Alphabet-owned AI drug discovery startup Isomorphic Labs is in early-stage talks for a new funding round that would value the company at no less than $40 billion, according to Bloomberg Technology. The company was spun out of Google DeepMind, linking the fundraising effort to one of Alphabet’s best-known artificial intelligence units. The report did not provide additional details on the size of the potential round, participating investors, or a timeline for closing. With discussions still at an early stage, the valuation and deal structure could change if negotiations continue. The development points to investor interest in AI-driven drug discovery companies, though the input only confirms the fundraising talks, the minimum valuation cited, and the company’s origin within Google DeepMind.
Alphabet-owned AI drug discovery startup Isomorphic Labs is in early talks for a new funding round at a valuation of at least $40 billion, according to Bloomberg Technology.
Isomorphic Labs was spun out of Google DeepMind. The input did not disclose further details about the financing.
This article was originally published by Bit.Fan. For more cryptocurrency news and market insights, visit www.bit.fan. Disclaimer:
The market information, project data, and third-party content displayed on this platform are for industry information sharing only and do not constitute any form of investment advice or return commitment.
Cryptocurrency trading carries high risks. Users should fully assess their risk tolerance and make independent decisions. All profits, losses, and legal responsibilities are borne by the users themselves.
